In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.

●Consolidated net sales totaled 222,584 million yen, an increase of 20,793 million yen (10.3%) year-on-year. Sales in the Mobility & Imaging Business Unit, Fine Chemicals Business Unit, and Life Science Business Unit all outperformed the previous fiscal year.
●Consolidated operating income increased by 13,064 million yen (178.1%) to 20,401 million yen compared to the pre-vious fiscal year.
●Consolidated ordinary income totaled 22,266 million yen, an increase of 9,704 million yen (77.3%) year-on-year. The increase was due to growth in consolidated operating income which exceeded the decrease in foreign exchange gains.
●Profit attributable to owners of parent was 17,508 million yen, an increase of 13,395 million yen (325.6%) year-on-year. The increase was mainly due to a gain on sales of investment securities.

(billions yen)	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03
R&D Expenses	13.0	13.9	12.0	12.5	11.0	12.4	13.0	13.3	19.8	15.1
R&D Expenses to net sales ratio	8.0%	8.7%	7.1%	7.2%	6.3%	7.2%	7.0%	6.7%	9.8%	6.8%
Capital Investments	13.4	11.5	16.4	16.6	14.5	8.3	11.5	23.5	17.7	26.6
Depreciation and Amortization	11.2	11.3	11.6	11.9	12.3	12.8	13.5	13.7	13.9	13.9